A clinical trial of OXS-C3550
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2018
Price : $35 *
At a glance
- Drugs OXS-C3550 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 15 Nov 2018 According to a GT Biopharma media release, the company is working towards beginning this trial in 2019.
- 13 Feb 2018 According to a GT Biopharma media release, this trial is expected to initiate in second half of 2018.
- 30 Jan 2018 New trial record